The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I/II study of BNC105P in combination with everolimus or following everolimus for progressive metastatic renal cell carcinoma following prior tyrosine kinase inhibitors.
T. E. Hutson
No relevant relationships to disclose
J. Sarantopoulos
No relevant relationships to disclose
T. Logan
No relevant relationships to disclose
G. Sonpavde
No relevant relationships to disclose
M. D. Galsky
No relevant relationships to disclose
C. Sweeney
Consultant or Advisory Role - Bionomics
D. C. Bibby
Employment or Leadership Position - Bionomics
Stock Ownership - Bionomics
G. Kremmidiotis
Employment or Leadership Position - Bionomics
Stock Ownership - Bionomics
E. E. Doolin
Employment or Leadership Position - Bionomics
N. M. Hahn
No relevant relationships to disclose